Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease, Real-World Data and Challenges

  • Redondo, Sara|||0000-0001-8967-7410
  • Esquirol, Albert|||0000-0002-6062-5980
  • Novelli, Silvana|||0000-0001-8750-0195
  • Caballero, Ana Carolina|||0000-0002-4950-5259
  • Garrido Diaz, Ana|||0000-0002-5297-8946
  • Oñate, Guadalupe|||0000-0003-2180-2371
  • López, Jordi
  • Moreno, Carol|||0000-0003-3275-0271
  • Saavedra, Silvana|||0000-0001-5699-0531
  • Granell, Miquel|||0000-0002-0366-3673
  • Briones Meijide, Javier|||0000-0003-2750-3735
  • Sierra, Jorge|||0000-0002-7966-0356
  • Martino Bofarull, Rodrigo|||0000-0001-5143-4042
  • García Cadenas, Irene|||0000-0002-2994-9055
Steroid-refractory (SR) chronic graft-versus-host disease (cGVHD) is a major obstacle in recipients of allogeneic stem cell transplantation (HCT). Ruxolitinib is the first agent to demonstrate superior efficacy to the best available therapy, but real-life data are still lacking. Here we describe the results of ruxolitinib compassionate use for the treatment of SR/steroid-dependent cGVHD in a tertiary care university hospital. In this retrospective single-center study, we evaluated the outcomes of 48 patients diagnosed with SR-cGVHD who were treated with ruxolitinib. Forty-seven (98%) had moderate-severe disease, and 27 (56%) had received ≥2 lines of prior therapy (excluding steroids). Results were analyzed using SPSS version 26.0.01 and R version 3.4.3. The overall response rate was 77% (37 of 48), with 15% (7 of 37) in complete remission. The median time to response was 2 months (range, 0.5 to 8 months). Steroid tapering was achieved in 26 patients (54%) and definitive discontinuation was achieved in 10 patients (21%) after a median of 20 months (range, 1.5 to 60 months). Toxicity was predominantly hematologic, including a 33% rate of anemia and a 17% rate of thrombocytopenia. Overall survival at 2 years was significantly higher in responders compared with nonresponders (88% [95% confidence interval (CI), 65% to 96%] versus 49% [95% CI, 12% to 78%]; P =.01). At last follow-up, tapering of ruxolitinib had been started in 8 of 37 responders (22%). Our experience supports the efficacy of ruxolitinib in the treatment of SR-cGVHD, along with its steroid-sparing effect and manageable toxicity. Gradual tapering of ruxolitinib seems feasible without cases of GVHD flare. More studies and longer follow-up are needed to confirm these data, as well as to identify the ideal dose adjustments in cases of toxicity.